Parkside Scientific Inc. is a New York City based clinical stage company developing novel “best-in-class” small molecule drugs that target bromodomain (BrD) proteins for epigenetic control of gene transcription in cancers and inflammatory diseases. 

Guided with Parkside’s proprietary drug discovery technology and unique insights into BrD biology, Parkside’s patented drugs are developed to target multiple protein activities unique for disease cells without disrupting normal cell activity. As a consequence of our novel approach, Parkside’s drugs have proven highly efficacious in animal studies, with the potential we believe for reduced or minimal side effects in humans, compared to many approved cancer drugs and other BrD inhibitors currently in clinical trials.

Using its unique approach, Parkside can target pervasive deadly diseases with no effective drug therapies, such as Hematological Malignancies, Enzalutamide-resistant Prostate Cancer (PCa) and Triple-Negative Breast Cancer (TNBC).  

Parkside’s most advanced program primarily targets (i) relapsed/refractory acute myeloid leukemia (AML), multiple myeloma (MM) and other blood cancers, and (ii) metastatic Prostate Cancer patients with androgen receptor-negative (AR-neg) tumors for which there is no effective drug treatment, including Enzalutamide (Xtandi), the current PCa SOC. Because all current PCa drugs inevitably suffer from drug resistance over time, Parkside’s target patient population for its drug encompasses virtually every PCa patient. 

Parkside’s most advanced drug compound has been cleared to start human clinical trials for AML, MM and other blood cancers. Patient enrollment is underway. Parkside’s other drugs for patients suffering with solid tumors (PCa and TNBC) and inflammatory diseases (Age-Related Macular Degeneration, Inflammatory Bowel Disease and Multiple Sclerosis) follow close behind in development. 

Parkside believes that its unique understanding of BrD biology and approach to developing novel compounds will results in a new class of drugs that importantly will provide viable, enduring therapeutic options—as opposed to temporary treatment—for many intractable solid tumors and inflammatory diseases, as well as blood cancers.  

For further information, please email: [email protected]